aBLA Filing Intelligence & Biosimilar Opportunity

Epkinly

Epcoritamab-Bysp

Anticancer

Injection

Epkinly is an injection used for certain types of blood cancer like large B-cell lymphoma. It helps immune cells find and destroy cancer cells.

Approval Date

19-May-23

Data Exclusivity Expiry

19-May-27

Market Exclusivity Expiry

19-May-35

Commercial snapshot

Market performance & projections

Revenue ($M)

650

CAGR (%)

0.428

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

961

2027

1516

2028

2095

2029

2703

2030

3239

2031

3787

2032

4354

Molecule profile

Details & specifications

Molecule

Epcoritamab-Bysp

Innovator

GENMAB AND ABBVIE

Dosage Form

Injection

Strength

4 mg/0.8 mL and 48 mg/0.8 mL

Therapeutic Category

Anticancer

Usage

To treat relapsed or refractory diffuse large B-cell lymphoma (not otherwise specified) and high-grade B-cell lymphoma after two or more lines of systemic therapy

Good to know

Frequently asked questions

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.

Why Spring Bio Solution

Intelligence you can file on

Verified regulatory data

Milestones tracked against primary FDA sources and refreshed continuously.

Analyst-built projections

Seven-year sales outlooks modeled by our pharma intelligence team.

First-to-file focus

Exclusivity windows framed around the decisions generics teams actually make.

Partnership on demand

From API sourcing to dossier support — one request starts the conversation.